Blood modifications associated with end stage renal disease duration, progression and cardiovascular mortality

dc.contributor.author	Αντωνέλου, Μαριάννα	el
dc.contributor.author	Γεωργατζάκου, Χαρά Τ.	el
dc.contributor.author	Τζουνάκας, Βασίλης Λ.	el
dc.contributor.author	Βελέντζας, Αθανάσιος Δ.	el
dc.contributor.author	Κόκκαλης, Απόστολος	el
dc.date.accessioned	2015-06-10T15:29:33Z
dc.date.available	2015-06-10T15:29:33Z
dc.date.issued	2015-06-10
dc.identifier.uri	http://hdl.handle.net/11400/15643
dc.rights	Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/us/	*
dc.source	http://www.sciencedirect.com/science/article/pii/S187439191400058X	en
dc.subject	Αλκαλική φωσφατάση
dc.subject	Καρδιαγγειακή θνησιμότητα
dc.subject	Πρωτεΐνες μεμβράνης
dc.subject	Οξειδωτικό στρες
dc.subject	Καρβονυλίωση των πρωτεϊνών
dc.subject	Ερυθρά αιμοσφαίρια
dc.subject	Alkaline phosphatase
dc.subject	Cardiovascular mortality
dc.subject	Membrane proteins
dc.subject	Oxidative stress
dc.subject	Protein carbonylation
dc.subject	Erythrocytes
dc.title	Blood modifications associated with end stage renal disease duration, progression and cardiovascular mortality	en
heal.type	journalArticle
heal.secondaryTitle	a 3-year follow-up pilot study	en
heal.classification	Καρδιολογία
heal.classification	Μικροβιολογία
heal.classification	Cardiology
heal.classification	Microbiology
heal.classificationURI	N/A-Καρδιολογία
heal.classificationURI	N/A-Μικροβιολογία
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh85020214
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh00005932
heal.keywordURI	http://id.loc.gov/authorities/subjects/sh85003597
heal.keywordURI	http://id.loc.gov/authorities/subjects/sh85083471
heal.keywordURI	http://id.loc.gov/authorities/subjects/sh2003008365
heal.keywordURI	http://id.loc.gov/authorities/subjects/sh85044747
heal.contributorName	Κριεμπάρδης, Αναστάσιος Γ.	el
heal.contributorName	Παπασιδέρη, Ι.	el
heal.identifier.secondary	DOI: 10.1016/j.jprot.2014.02.009
heal.language	en
heal.access	campus
heal.recordProvider	Τεχνολογικό Εκπαιδευτικό Ίδρυμα Αθήνας. Σχολή Επαγγελμάτων Υγείας και Πρόνοιας. Τμήμα Ιατρικών Εργαστηρίων	el
heal.publicationDate	2014-04-14
heal.bibliographicCitation	Antonelou, M.H., Georgatzakou, H.T., Tzounakas, V.L., Velentzas, A.D., Kokkalis, A.C et al. (2014) Blood modifications associated with end stage renal disease duration, progression and cardiovascular mortality: A 3-year follow-up pilot study. Journal of Proteomics. [Online] 101, pp.88-101.Available from: http://www.sciencedirect.com [Accessed 10/06/2015]	en
heal.abstract	Chronic kidney disease is a risk factor for cardiovascular mortality. This study uncovers pieces of hematological and erythrocyte protein variability observed in end stage renal disease (ESRD) in relation to disease progression/duration and mortality. Using a variety of experimental approaches, erythropoietin/dialysis-treated patients were compared to healthy individuals and had been followed for 36. months. During that period, half of the patients died from cardiovascular diseases. The high levels of uremic toxins in those patients were associated with damaged erythrocytes, bad tolerance and poor response to hemodialysis therapy. The postmortem study revealed significant variation in alkaline phosphatase, duration of dialysis, erythrocyte transformation and intracellular hemoglobin concentration compared to the survived patients. The erythrocyte proteins showed substantial remodeling characteristic of pathologic regulation of cell hydration and susceptibility to the dialysis-induced oxidation defects. According to the follow-up study, duration of hemodialysis was associated with a trend towards increased intracellular hemoglobin concentration, membrane expression of glucose transporter-1 and stomatin as well as lower levels of circulating stomatocytes. The uremic index variation in long survived patients is accurately reflected in plasma and erythrocyte oxidative stress modifications. The ESRD patients exhibit impressive compensatory responses to the chronic challenges of the uremic milieu. Biological significance: This study demonstrates novel blood modifications probably associated with the duration of erythropoietin/hemodialysis treatment, disease progression and cardiovascular mortality in end stage renal disease. The observed variability adds new pieces to the erythrocyte pathophysiology puzzle in end stage renal disease and suggests novel hematologic and proteomic factors for consideration in future large scale studies on cardiovascular morbidity and mortality candidate biomarkers in uremic patients.	en
heal.publisher	Elsevier	en
heal.journalName	Journal of Proteomics	en
heal.journalType	peer-reviewed
heal.fullTextAvailability	true